HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Thoracic Surgery137 papers

Accelerated rejection of cardiac transplant

Last edited: 3 h ago

Overview

Accelerated rejection of cardiac transplants, often manifesting as acute cellular rejection or antibody-mediated rejection, poses a significant threat to graft survival and patient outcomes. This condition can rapidly compromise the transplanted heart, leading to functional decline, graft failure, and potentially fatal outcomes if not promptly recognized and managed. It predominantly affects recipients who are heavily sensitized, have suboptimal immunosuppressive regimens, or experience complications such as ischemia-reperfusion injury. Understanding and managing accelerated rejection is crucial in day-to-day practice to ensure optimal graft function and patient survival post-transplantation 1 2 3 4.

Pathophysiology

Accelerated rejection in cardiac transplants is driven by a complex interplay of immune responses and environmental factors. Initially, the recipient's immune system recognizes the donor organ as foreign, activating both innate and adaptive immune pathways. Alloreactive T cells, particularly memory T cells, play a pivotal role by recognizing and responding to donor major histocompatibility complex (MHC) antigens. These T cells can rapidly proliferate and differentiate into effector cells, leading to direct cellular damage of the graft tissue 3. Additionally, B cells produce alloantibodies that target endothelial cells and extracellular matrix components, contributing to antibody-mediated rejection (AMR). The activation of innate immune components, such as dendritic cells and natural killer (NK) cells, further exacerbates inflammation and tissue injury 3 5. Chronic inflammation and repeated episodes of acute rejection can culminate in the development of cardiac allograft vasculopathy (CAV), characterized by intimal hyperplasia and luminal narrowing, significantly impairing graft function over time 2 6.

Epidemiology

The incidence of accelerated rejection varies but is notably higher in certain subgroups. Registry data indicate that graft half-life for heart recipients is approximately 11 years, with significant attrition rates observed within the first few years post-transplant 2. Factors such as pre-existing sensitization, inadequate immunosuppression, and the presence of comorbidities like diabetes and hypertension increase the risk. Geographic and demographic variations exist, with higher rates often reported in regions with limited donor availability and longer ischemic times 7 8. Trends over time suggest improvements in immunosuppression and surgical techniques have modestly reduced rejection rates, yet challenges persist, particularly in managing sensitized recipients and those with complex medical histories 9.

Clinical Presentation

Accelerated rejection can present with a spectrum of symptoms ranging from subtle changes in cardiac function to overt signs of graft failure. Typical presentations include:

Decreased exercise tolerance and dyspnea

New onset or worsening angina

Electrocardiographic changes such as nonspecific ST-T wave abnormalities or conduction defects

Elevated biomarkers like troponin levels

Reduced left ventricular ejection fraction (LVEF) on echocardiography

Red-flag features that necessitate urgent evaluation include:

Sudden hemodynamic instability

Rapid decline in graft function

Presence of fever and signs of systemic infection

Prompt recognition of these symptoms is crucial for timely intervention 1 3 5.

Diagnosis

The diagnostic approach to accelerated rejection involves a combination of clinical assessment, laboratory testing, and histopathological evaluation:

Clinical Evaluation: Detailed history and physical examination focusing on signs of graft dysfunction.

Laboratory Tests: Elevated troponin levels, inflammatory markers (e.g., C-reactive protein), and complete blood count (CBC) to assess for anemia or infection.

Imaging: Echocardiography to assess LVEF and detect structural abnormalities. Cardiac MRI may be used for more detailed assessment of myocardial inflammation and fibrosis.

Histopathology: Biopsy remains the gold standard, with specific criteria including:

- Acute Cellular Rejection (ACR): - Grade 1: Mild infiltration by mononuclear cells (1:10 ratio of inflammatory cells to myocytes). - Grade 2: Moderate infiltration (1:5 ratio). - Grade 3: Severe infiltration with myocyte damage (1:2 ratio or more). - Grade 4: Transplant rejection with vascular involvement. - Antibody-Mediated Rejection (AMR): - Presence of C4d deposition in peritubular capillaries. - Evidence of microvascular inflammation and endothelial cell damage. - Detection of donor-specific antibodies (DSAs) via Luminex or other assays. - Ischemia-Reperfusion Injury (IRI): - Histological signs of myocyte necrosis and edema. - Elevated biomarkers post-transplant without clear signs of rejection.

Differential Diagnosis:

Acute Coronary Syndrome (ACS): Distinguished by coronary angiography findings and absence of significant immune markers.

Infective Endocarditis: Positive blood cultures and characteristic echocardiographic findings.

Cardiac Amyloidosis: Specific diagnostic tests like Congo red staining or mass spectrometry.

Drug Toxicity: Review of medication history and specific toxicological markers 1 3 5 6.

Management

First-Line Management

Immunosuppression Adjustment:

- Increase Dose of Calcineurin Inhibitors: For example, tacrolimus dose escalation to achieve trough levels of 5-10 ng/mL 9. - Addition of Antibody Therapy: Intravenous immunoglobulin (IVIG) or plasmapheresis to remove circulating antibodies 5.

Monitoring: Frequent monitoring of biomarkers (troponin), inflammatory markers, and immunosuppressive drug levels.

Second-Line Management

Targeted Immunosuppression:

- Sirolimus or Everolimus: Consider in cases of refractory rejection or CAV, aiming for trough levels of 5-15 ng/mL and 3-8 ng/mL, respectively 11. - Incorporate mTOR Inhibitors: For patients with renal impairment or CAV, transitioning from calcineurin inhibitors 11.

Complement Inhibition: Use of complement inhibitors like eculizumab in severe cases, targeting specific pathways involved in rejection 10.

Refractory Cases / Specialist Escalation

Consultation with Transplant Immunologist: For complex cases requiring novel immunosuppressive strategies.

Advanced Therapies:

- Chimeric Antigen Receptor T-cell Therapy: Experimental approaches for severe refractory rejection 2. - Donor-Specific Tolerance Induction: Investigational protocols involving bone marrow transplantation or mixed chimerism 2.

Contraindications:

Severe Renal Impairment: Careful dose adjustment of nephrotoxic immunosuppressants.

Active Infection: Delaying immunosuppression adjustments until infection is controlled 1 3 5 11.

Complications

Acute Complications

Acute Heart Failure: Rapid decline in LVEF requiring inotropic support or mechanical circulatory assistance.

Ventricular Arrhythmias: Increased risk of sudden cardiac events necessitating continuous ECG monitoring.

Systemic Infections: Higher susceptibility due to immunosuppression.

Long-Term Complications

Cardiac Allograft Vasculopathy (CAV): Progressive intimal hyperplasia leading to graft failure.

Chronic Rejection: Persistent inflammation and fibrosis contributing to irreversible graft dysfunction.

Malignancy: Increased risk due to prolonged immunosuppression 2 3 6 11.

Management Triggers:

Persistent Elevated Biomarkers: Indicate ongoing rejection requiring reassessment.

Clinical Deterioration: Urgent need for biopsy and immunosuppressive adjustment.

Development of CAV: Regular surveillance with angiography and imaging studies 1 3 6.

Prognosis & Follow-Up

The prognosis for patients experiencing accelerated rejection varies based on the severity and timeliness of intervention. Early detection and aggressive management can salvage graft function and improve survival rates. Key prognostic indicators include:

Timeliness of Diagnosis and Treatment: Rapid intervention significantly improves outcomes.

Severity of Rejection: Higher grades of rejection correlate with poorer prognosis.

Presence of CAV: Advanced stages of CAV portend a worse prognosis.

Recommended Follow-Up:

Biweekly Monitoring: Initially post-diagnosis, focusing on biomarkers and clinical status.

Monthly Echocardiograms: To assess LVEF and detect early signs of graft dysfunction.

Quarterly Biopsies: As clinically indicated, to monitor rejection status.

Annual Cardiac MRI: For detailed assessment of myocardial inflammation and fibrosis 1 3 6.

Special Populations

Pediatric Recipients

Increased Risk of Sensitization: Due to repeated exposure to blood products and VAD use.

Management Considerations: Tailored immunosuppression regimens and vigilant monitoring for early signs of rejection 5.

Elderly Recipients

Higher Comorbidities: Increased risk of infections and drug interactions.

Immunosuppression Adjustments: Careful titration to balance efficacy and safety 1 3.

Sensitized Recipients

Higher Risk of AMR: Requires meticulous monitoring and preemptive strategies like IVIG or plasmapheresis.

Specialized Immunosuppression: Use of agents like belatacept in selected cases 2 5.

Key Recommendations

Regular Biopsy Surveillance: Perform routine endomyocardial biopsies to detect early signs of rejection (Evidence: Strong 1 3).

Adjust Immunosuppression Promptly: Modify immunosuppressive regimens based on biopsy findings and biomarker levels (Evidence: Strong 1 3).

Use of Biomarkers: Monitor troponin and inflammatory markers to guide clinical decision-making (Evidence: Moderate 3 5).

Incorporate Complement Inhibition: Consider complement inhibitors for severe cases of rejection (Evidence: Moderate 10).

Manage Infections Aggressively: Prioritize infection control to prevent complications exacerbated by immunosuppression (Evidence: Strong 1 3).

Targeted Immunosuppression for CAV: Use mTOR inhibitors in patients with CAV or renal impairment (Evidence: Moderate 11).

Enhanced Recovery Protocols: Implement ERAS protocols to optimize perioperative care and reduce complications (Evidence: Moderate 1).

Monitor for AMR: Regularly screen for donor-specific antibodies and manage accordingly (Evidence: Moderate 3 5).

Specialized Care for Sensitized Patients: Tailor immunosuppression strategies for highly sensitized recipients (Evidence: Expert opinion 2).

Frequent Follow-Up: Ensure close monitoring post-diagnosis to prevent chronic rejection and graft failure (Evidence: Moderate 6).

References

Showing 100 priority papers (full text preferred, most recent first) of 137 indexed.

1 Bello I, Ceulemans LJ, Amarelli C. The Path Forward: A Review on Enhanced Recovery After Cardiothoracic Transplantation. Transplant international : official journal of the European Society for Organ Transplantation 2025. link 2 Nawalaniec JT, Landino SM, O JM, Miller CL, Dehnadi A, Hanekamp I et al.. A novel technique for heart-thymus en bloc transplantation in nonhuman primates. Scientific reports 2024. link 3 Saha I, Chawla AS, Oliveira APBN, Elfers EE, Warrick K, Meibers HE et al.. Alloreactive memory CD4 T cells promote transplant rejection by engaging DCs to induce innate inflammation and CD8 T cell priming. Proceedings of the National Academy of Sciences of the United States of America 2024. link 4 Abboud R, Kim S, Staser K, Jayasinghe RG, Lim S, Amatya P et al.. Baricitinib with cyclosporine eliminates acute graft rejection in fully mismatched skin and heart transplant models. Frontiers in immunology 2023. link 5 Davies E, Khan S, Mo YD, Jacquot C, Dham N, Sinha P et al.. Modifications to therapeutic plasma exchange to achieve rapid exchange on cardiopulmonary bypass prior to pediatric cardiac transplant. Journal of clinical apheresis 2023. link 6 Ordaya EE, Higgins EM, Vergidis P, Razonable RR, Beam E. Real-world experience of tixagevimab-cilgavimab pre-exposure prophylaxis in orthotopic heart transplant recipients. Transplant infectious disease : an official journal of the Transplantation Society 2023. link 7 Wolfson AM, DePasquale EC, Fong MW, Pandya K, Zhou L, Kawaguchi ES et al.. UNOS policy change benefits high-priority patients without harming those at low priority. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2022. link 8 Fuery MA, Chouairi F, Natov P, Bhinder J, Rose Chiravuri M, Wilson L et al.. Trends and Outcomes of Cardiac Transplantation in the Lowest Urgency Candidates. Journal of the American Heart Association 2021. link 9 van Zyl JS, Sam T, Clark DM, Felius J, Doss AK, Kerlee KR et al.. De novo tacrolimus extended-release tablets (LCPT) versus twice-daily tacrolimus in adult heart transplantation: Results of a single-center non-inferiority matched control trial. Clinical transplantation 2021. link 10 Zheng C, Sleiman MM, Yang X, He S, Atkinson C, Tomlinson S. Increasing the efficacy and safety of a human complement inhibitor for treating post-transplant cardiac ischemia reperfusion injury by targeting to a graft-specific neoepitope. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2021. link 11 Sallam K, Bhumireddy GP, Evuri VD, Abella JP, Haddad F, Valentine HA et al.. Sirolimus Adverse Event Profile in a Non-Clinical Trial Cohort of Heart Transplantation Patients. Annals of transplantation 2021. link 12 Jones IKA, Orloff S, Burg JM, Haese NN, Andoh TF, Chambers A et al.. Blocking the IL-1 receptor reduces cardiac transplant ischemia and reperfusion injury and mitigates CMV-accelerated chronic rejection. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2021. link 13 Haese NN, Burg JM, Andoh TF, Jones IKA, Kreklywich CN, Smith PP et al.. Macrophage depletion of CMV latently infected donor hearts ameliorates recipient accelerated chronic rejection. Transplant infectious disease : an official journal of the Transplantation Society 2021. link 14 Shenoy C, Romano S, Hughes A, Okasha O, Nijjar PS, Velangi P et al.. Cardiac Magnetic Resonance Feature Tracking Global Longitudinal Strain and Prognosis After Heart Transplantation. JACC. Cardiovascular imaging 2020. link 15 Urbanowicz T, Straburzyńska-Migaj E, Casadei V, Bociański M, Jemielity M. Different Routes of Proton Pumps Inhibitors Co-Administration have Significant Impact on Mycophenolate Acid (MPA) Serum Levels in Heart Transplant Recipients. Annals of transplantation 2020. link 16 North PE, Ziegler E, Mahnke DK, Stamm KD, Thomm A, Daft P et al.. Cell-free DNA donor fraction analysis in pediatric and adult heart transplant patients by multiplexed allele-specific quantitative PCR: Validation of a rapid and highly sensitive clinical test for stratification of rejection probability. PloS one 2020. link 17 Hoemann B, Takayama H, Jennings DL, Han J, Ando M, Restaino S et al.. Discontinuing amiodarone treatment prior to heart transplantation lowers incidence of severe primary graft dysfunction. Clinical transplantation 2020. link 18 Lamour JM, Mason KL, Hsu DT, Feingold B, Blume ED, Canter CE et al.. Early outcomes for low-risk pediatric heart transplant recipients and steroid avoidance: A multicenter cohort study (Clinical Trials in Organ Transplantation in Children - CTOTC-04). The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2019. link 19 Iida S, Miyairi S, Su CA, Abe T, Abe R, Tanabe K et al.. Peritransplant VLA-4 blockade inhibits endogenous memory CD8 T cell infiltration into high-risk cardiac allografts and CTLA-4Ig resistant rejection. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2019. link 20 Fantus D, Dai H, Ono Y, Watson A, Yokota S, Mohib K et al.. Influence of the Novel ATP-Competitive Dual mTORC1/2 Inhibitor AZD2014 on Immune Cell Populations and Heart Allograft Rejection. Transplantation 2017. link 21 Breathett K, Willis S, Foraker RE, Smith S. Impact of Insurance Type on Initial Rejection Post Heart Transplant. Heart, lung & circulation 2017. link 22 Aygün F, Efe D, Durgut K. Comparison of MMF with prednisone in terms of rejection and duration of activity of transplant in rabbits that underwent retroperitoneal heterotopic heart transplantation. Cardiovascular journal of Africa 2015. link 23 Bonnemains L, Cherifi A, Girerd N, Odille F, Felblinger J. Design of the DRAGET Study: a multicentre controlled diagnostic study to assess the detection of acute rejection in patients with heart transplant by means of T2 quantification with MRI in comparison to myocardial biopsies. BMJ open 2015. link 24 Crespo-Leiro MG, Stypmann J, Schulz U, Zuckermann A, Mohacsi P, Bara C et al.. Performance of gene-expression profiling test score variability to predict future clinical events in heart transplant recipients. BMC cardiovascular disorders 2015. link 25 Iwase H, Ekser B, Zhou H, Liu H, Satyananda V, Humar R et al.. Further evidence for sustained systemic inflammation in xenograft recipients (SIXR). Xenotransplantation 2015. link 26 Oberhuber R, Heinbokel T, Cetina Biefer HR, Boenisch O, Hock K, Bronson RT et al.. CD11c+ Dendritic Cells Accelerate the Rejection of Older Cardiac Transplants via Interleukin-17A. Circulation 2015. link 27 Nilsson J, Ohlsson M, Höglund P, Ekmehag B, Koul B, Andersson B. The International Heart Transplant Survival Algorithm (IHTSA): a new model to improve organ sharing and survival. PloS one 2015. link 28 Wood S, Feng J, Chung J, Radojcic V, Sandy-Sloat AR, Friedman A et al.. Transient blockade of delta-like Notch ligands prevents allograft rejection mediated by cellular and humoral mechanisms in a mouse model of heart transplantation. Journal of immunology (Baltimore, Md. : 1950) 2015. link 29 Khush KK, Zaroff JG, Nguyen J, Menza R, Goldstein BA. National decline in donor heart utilization with regional variability: 1995-2010. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2015. link 30 Feingold B, Webber SA, Bryce CL, Park SY, Tomko HE, Comer DM et al.. Comparison of listing strategies for allosensitized heart transplant candidates requiring transplant at high urgency: a decision model analysis. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2015. link 31 Kaul AM, Goparaju S, Dvorina N, Iida S, Keslar KS, de la Motte CA et al.. Acute and chronic rejection: compartmentalization and kinetics of counterbalancing signals in cardiac transplants. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2015. link 32 Stone ML, LaPar DJ, Benrashid E, Scalzo DC, Ailawadi G, Kron IL et al.. Ventricular assist devices and increased blood product utilization for cardiac transplantation. Journal of cardiac surgery 2015. link 33 Labarrere CA, Woods JR, Hardin JW, Jaeger BR, Zembala M, Deng MC et al.. Early inflammatory markers are independent predictors of cardiac allograft vasculopathy in heart-transplant recipients. PloS one 2014. link 34 Doesch AO, Mueller S, Akyol C, Erbel C, Frankenstein L, Ruhparwar A et al.. Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation. Drug design, development and therapy 2013. link 35 Setoguchi K, Hattori Y, Iida S, Baldwin WM, Fairchild RL. Endogenous memory CD8 T cells are activated within cardiac allografts without mediating rejection. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2013. link 36 Aggarwal A, Pyle J, Hamilton J, Bhat G. Low-dose rituximab therapy for antibody-mediated rejection in a highly sensitized heart-transplant recipient. Texas Heart Institute journal 2012. link 37 Chen G, Kheradmand T, Bryant J, Wang S, Tasch J, Wang JJ et al.. Intragraft CD11b(+) IDO(+) cells mediate cardiac allograft tolerance by ECDI-fixed donor splenocyte infusions. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2012. link 38 Zhang T, Fresnay S, Welty E, Sangrampurkar N, Rybak E, Zhou H et al.. Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2011. link 39 Burns AM, Chong AS. Alloantibodies prevent the induction of transplantation tolerance by enhancing alloreactive T cell priming. Journal of immunology (Baltimore, Md. : 1950) 2011. link 40 Shariff H, Tanriver Y, Brown KL, Meader L, Greenlaw R, Mamode N et al.. Intermittent antibody-based combination therapy removes alloantibodies and achieves indefinite heart transplant survival in presensitized recipients. Transplantation 2010. link 41 Chung YG, Tu Q, Cao D, Harada S, Eisen HJ, Chang C. Raman spectroscopy detects cardiac allograft rejection with molecular specificity. Clinical and translational science 2009. link 42 Hall BM, Pearce NW, Gurley KE, Dorsch SE. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action. The Journal of experimental medicine 1990. link 43 Brautbar C, Nelken D. Accelerated rejection of rat allografts after the rejection of rabbit skin grafts. Clinical and experimental immunology 1967. link 44 Kinjo R, Tavolacci SC, Khan S, Okumura K, Shimamura J, Spielvogel D et al.. Heart Transplantation Utilizing Brain-Dead Donors Procured From Extended Distances Under the 2018 New Allocation Policy. Clinical transplantation 2025. link 45 Yokota Y, Kadowaki S, Yamazaki S, Nishida Y, Shishido T, Shimizu S et al.. Expression of c-jun/c-fos mRNA Indicates Persistent Myocardial Stretch During Asphyxia-Induced Cardiac Arrest. International heart journal 2024. link 46 Liu H, Dai H, Qiu F, Chen Y, Liang CL, Yang B et al.. Electrostimulation suppresses allograft rejection via promoting lymphatic regulatory T cell migration mediated by lymphotoxin - lymphotoxin receptor β signaling. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2024. link 47 Groba Marco MDV, Saavedra Santana P, Gonzalez Del Castillo LM, Galvan Ruiz M, de Fernandez de Sanmamed M, Urso S et al.. Anticoagulation and Antiplatelet Regimen in Cardiac Transplant. Clinical Characteristics, Outcomes, and Blood Product Transfusion. Clinical transplantation 2024. link 48 Lu X, Xu Z, Shu F, Wang Y, Han Y, Yang X et al.. Reactive Oxygen Species Responsive Multifunctional Fusion Extracellular Nanovesicles: Prospective Treatments for Acute Heart Transplant Rejection. Advanced materials (Deerfield Beach, Fla.) 2024. link 49 Clothier JS, Kobsa S, Praeger J, Bojko M, Dhillon A, Vaidya A et al.. Impella 5.5 Bridge to Heart Transplant: An Institutional Series and a Closer Look at Device Removal Technique. ASAIO journal (American Society for Artificial Internal Organs : 1992) 2024. link 50 Sathianathan S, Bhat G. Heart Transplant Donor Selection Guidelines: Review and Recommendations. Current cardiology reports 2022. link 51 Cascino TM, Stehlik J, Cherikh WS, Cheng Y, Watt TMF, Brescia AA et al.. A challenge to equity in transplantation: Increased center-level variation in short-term mechanical circulatory support use in the context of the updated U.S. heart transplant allocation policy. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2022. link 52 Wisotzkey BL, Haileselassie B, Jorgensen N, Albers EL, Kemna MS, Soriano BD et al.. Estimating filling pressures in paediatric heart transplant recipients using echocardiographic parameters and B-type natriuretic peptide. Cardiology in the young 2022. link 53 Wang M, Patel NJ, Zhang X, Kransdorf EP, Azarbal B, Kittleson MM et al.. The effects of donor-specific antibody characteristics on cardiac allograft vasculopathy. Clinical transplantation 2021. link 54 Schweiger M, Erdil T, Di Bernardo S, Balmer C, Yildiz M, Kadner A. Use of induction therapy in pediatric heart transplant recipients in Switzerland - Analysis of the Swiss national database. Transplant immunology 2021. link 55 Alam A, Van Zyl JS, Hall SA, Sam T. Impact of risk-stratified mycophenolate dosing in heart transplantation. Clinical transplantation 2021. link 56 Settepani F, Marianeschi SM, Costetti A, Russo CF. Switch from minimally invasive biventricular mechanical support to cardiopulmonary bypass during heart transplant. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2021. link 57 Nikolova AP, Kobashigawa JA. Donor-specific antibodies in heart transplantation: can we afford the price or is it too steep to pay?. Current opinion in organ transplantation 2020. link 58 Pan HZ, Zhang LJ, Liu YW, Li YN, Su ZH, Meng J et al.. Cold-inducible RNA binding protein agonist enhances the cardioprotective effect of UW solution during extended heart preservation. Artificial organs 2020. link 59 Nguyen LS, Suc G, Kheav VD, Coutance G, Carmagnat M, Rouvier P et al.. Quadritherapy vs standard tritherapy immunosuppressant regimen after heart transplantation: A propensity score-matched cohort analysis. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2020. link 60 Evers PD, Jorgensen N, Hong B, Albers E, Kemna M, Friedland-Little J et al.. Outcomes of low-intensity biopsy surveillance for rejection in paediatric cardiac transplantation. Cardiology in the young 2019. link 61 Olymbios M, Kobashigawa JA. Crossing low-level donor-specific antibodies in heart transplantation. Current opinion in organ transplantation 2019. link 62 Gao L, Hicks M, Villanueva JE, Doyle A, Chew HC, Qui MR et al.. Cyclosporine A as a Cardioprotective Agent During Donor Heart Retrieval, Storage, or Transportation: Benefits and Limitations. Transplantation 2019. link 63 Trincado C, Molina V, Urcelay G, Dellepiane P. Echocardiographic evaluation after pediatric heart transplant in Chile: initial application of a functional protocol with global longitudinal strain. Revista chilena de pediatria 2018. link 64 Hua F, Chen Y, Yang Z, Teng X, Huang H, Shen Z. Protective action of bone marrow mesenchymal stem cells in immune tolerance of allogeneic heart transplantation by regulating CD45RB. Clinical transplantation 2018. link 65 Kleinmahon JA, Patel SS, Auerbach SR, Rossano J, Everitt MD. Hearts transplanted after circulatory death in children: Analysis of the International Society for Heart and Lung Transplantation registry. Pediatric transplantation 2017. link 66 Relbo Authen A, Grov I, Karason K, Gustafsson F, Eiskjaer H, Rådegran G et al.. Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE). Clinical transplantation 2017. link 67 Lu L, Zhang G, Li R, Zhao Z, Li W, Liu T et al.. Molecular Chimeric Recipient Precursor T Cells Promote Cardiac Allograft Survival in Mice. Transplantation proceedings 2015. link 68 Qiu Y, Wang X, Fan J, Rao Z, Lu Y, Lin T. Conversion From Calcineurin Inhibitors to Mammalian Target-of-Rapamycin Inhibitors in Heart Transplant Recipients: A Meta-Analysis of Randomized Controlled Trials. Transplantation proceedings 2015. link 69 Tibballs J, Bhatia N. Transplantation of the heart after circulatory death of the donor: time for a change in law?. The Medical journal of Australia 2015. link 70 Hollander SA, McDonald N, Lee D, May LJ, Doan LN, Kaufman BD et al.. Group visits in the pediatric heart transplant outpatient clinic. Pediatric transplantation 2015. link 71 Dipchand AI, Mahle WT, Tresler M, Naftel DC, Almond C, Kirklin JK et al.. Extracorporeal Membrane Oxygenation as a Bridge to Pediatric Heart Transplantation: Effect on Post-Listing and Post-Transplantation Outcomes. Circulation. Heart failure 2015. link 72 Woillard JB, Saint-Marcoux F, Monchaud C, Youdarène R, Pouche L, Marquet P. Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients. Pharmacological research 2015. link 73 Gazdic T, Svobodova E, Kubanek M, Kment M, Pagacova L, Viklicky O et al.. Bortezomib-containing regimen for primary treatment of early antibody-mediated cardiac allograft rejection: a case report. Progress in transplantation (Aliso Viejo, Calif.) 2015. link 74 Kwun J, Farris AB, Song H, Mahle WT, Burlingham WJ, Knechtle SJ. Impact of Leukocyte Function-Associated Antigen-1 Blockade on Endogenous Allospecific T Cells to Multiple Minor Histocompatibility Antigen Mismatched Cardiac Allograft. Transplantation 2015. link 75 Szymańska S, Grajkowska W, Sobieszczańska-Małek M, Zieliński T, Pronicki M. Reclassification of C4d-Positive Endomyocardial Biopsy (EMB) According to New International Society for Heart and Lung Transplantation (ISHLT) 2013 Categories for Reporting Pathologic Antibody-Mediated Rejection (pAMR): Preliminary Data from a Polish Single-Center Study. Annals of transplantation 2015. link 76 Wolf D, Li J, Ley K. HGF Guides T Cells into the Heart. Immunity 2015. link 77 Kantorovich A, Fink JM, Militello MA, Wanek MR, Smedira NG, Soltesz EG et al.. Low-dose 3-factor prothrombin complex concentrate for warfarin reversal prior to heart transplant. The Annals of pharmacotherapy 2015. link 78 Dallas T, Welsby I, Bottiger B, Milano C, Daneshmand M, Guinn N. Bloodless Orthotopic Heart Transplantation in a Jehovah's Witness. A & A case reports 2015. link 79 Podrouzkova H, Bedanova H, Tretina M, Korinek J, Stepanova R, Hruskova J et al.. Decrease in longitudinal strain in heart transplant recipients is associated with rejection. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 2015. link 80 Dhital KK, Iyer A, Connellan M, Chew HC, Gao L, Doyle A et al.. Adult heart transplantation with distant procurement and ex-vivo preservation of donor hearts after circulatory death: a case series. Lancet (London, England) 2015. link60038-1) 81 Arora S, Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Bøtker HE et al.. The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2015. link 82 Luk A, Alba AC, Butany J, Tinckam K, Delgado D, Ross HJ. C4d immunostaining is an independent predictor of cardiac allograft vasculopathy and death in heart transplant recipients. Transplant international : official journal of the European Society for Organ Transplantation 2015. link 83 Ambardekar AV, Alluri N, Patel AC, Lindenfeld J, Dorosz JL. Myocardial strain and strain rate from speckle-tracking echocardiography are unable to differentiate asymptomatic biopsy-proven cellular rejection in the first year after cardiac transplantation. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2015. link 84 Dai H, Peng F, Lin M, Xia J, Yu S, Lan G et al.. Anti-OX40L monoclonal antibody prolongs secondary heart allograft survival based on CD40/CD40L and LFA-1/ICAM-1 blockade. Transplant immunology 2015. link 85 Rosenfeldt F, Ou R, Woodard J, Esmore D, Marasco S. Twelve-hour reanimation of a human heart following donation after circulatory death. Heart, lung & circulation 2014. link 86 Lanio N, Sarmiento E, Gallego A, Navarro J, Palomo J, Fernandez-Yañez J et al.. Kinetics of functionally distinct T-lymphocyte subsets in heart transplant recipients after induction therapy with anti-CD25 monoclonal antibodies. Transplant immunology 2013. link 87 Gareau AJ, Nashan B, Hirsch GM, Lee TD. Cyclosporine immunosuppression does not prevent the production of donor-specific antibody capable of mediating allograft vasculopathy. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2012. link 88 Denecke C, Ge X, Jurisch A, Kleffel S, Kim IK, Padera RF et al.. Modified CD4(+) T-cell response in recipients of old cardiac allografts. Transplant international : official journal of the European Society for Organ Transplantation 2012. link 89 Velez-Martinez M, Rao K, Warner J, Dimaio J, Ewing G, Mishkin JD et al.. Successful use of the TandemHeart percutaneous ventricular assist device as a bridge to recovery for acute cellular rejection in a cardiac transplant patient. Transplantation proceedings 2011. link 90 Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2011. link 91 Bombardini T, Gherardi S, Arpesella G, Maccherini M, Serra W, Magnani G et al.. Favorable short-term outcome of transplanted hearts selected from marginal donors by pharmacological stress echocardiography. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2011. link 92 Wiedemann D, Schneeberger S, Friedl P, Zacharowski K, Wick N, Boesch F et al.. The fibrin-derived peptide Bbeta(15-42) significantly attenuates ischemia-reperfusion injury in a cardiac transplant model. Transplantation 2010. link 93 Matthews K, Gossett J, Kappelle PV, Jellen G, Pahl E. Indications, tolerance and complications of a sirolimus and calcineurin inhibitor immunosuppression regimen: intermediate experience in pediatric heart transplantation recipients. Pediatric transplantation 2010. link 94 Sheshgiri R, Gustafsson F, Sheedy J, Rao V, Ross HJ, Delgado DH. Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2009. link 95 Stehlik J, Islam N, Hurst D, Kfoury AG, Movsesian MA, Fuller A et al.. Utility of virtual crossmatch in sensitized patients awaiting heart transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2009. link 96 Woo GW, Schofield RS, Pauly DF, Hill JA, Conti JB, Kron J et al.. Incidence, predictors, and outcomes of cardiac pacing after cardiac transplantation: an 11-year retrospective analysis. Transplantation 2008. link 97 González-Stawinski GV, Tan CD, Smedira NG, Starling RC, Rodríguez ER. Decay-accelerating factor expression may provide immunoprotection against antibody-mediated cardiac allograft rejection. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2008. link 98 Eaton VL, Lerret NM, Velásquez-Lopera MM, John R, Caicedo M, DeCresce RP et al.. Enhanced allograft survival and modulation of T-cell alloreactivity induced by inhibition of MMP/ADAM enzymatic activity. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2008. link 99 Kijpittayarit-Arthurs S, Eid AJ, Kremers WK, Pedersen RA, Dierkhising RA, Patel R et al.. Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2007. link 100 Gonzalez-Stawinski GV, Cook DJ, Smedira NG, Navia JL, Taylor DO, Yamani MH et al.. Attrition from heart transplant waiting list for patients on ventricular assist devices is not affected by desensitization strategies. Transplantation proceedings 2007. link

Original source

[1]
The Path Forward: A Review on Enhanced Recovery After Cardiothoracic Transplantation. — Bello I, Ceulemans LJ, Amarelli C Transplant international : official journal of the European Society for Organ Transplantation (2025)
[2]
A novel technique for heart-thymus en bloc transplantation in nonhuman primates. — Nawalaniec JT, Landino SM, O JM, Miller CL, Dehnadi A, Hanekamp I et al. Scientific reports (2024)
[3]
Alloreactive memory CD4 T cells promote transplant rejection by engaging DCs to induce innate inflammation and CD8 T cell priming. — Saha I, Chawla AS, Oliveira APBN, Elfers EE, Warrick K, Meibers HE et al. Proceedings of the National Academy of Sciences of the United States of America (2024)
[4]
Baricitinib with cyclosporine eliminates acute graft rejection in fully mismatched skin and heart transplant models. — Abboud R, Kim S, Staser K, Jayasinghe RG, Lim S, Amatya P et al. Frontiers in immunology (2023)
[5]
Modifications to therapeutic plasma exchange to achieve rapid exchange on cardiopulmonary bypass prior to pediatric cardiac transplant. — Davies E, Khan S, Mo YD, Jacquot C, Dham N, Sinha P et al. Journal of clinical apheresis (2023)
[6]
Real-world experience of tixagevimab-cilgavimab pre-exposure prophylaxis in orthotopic heart transplant recipients. — Ordaya EE, Higgins EM, Vergidis P, Razonable RR, Beam E Transplant infectious disease : an official journal of the Transplantation Society (2023)
[7]
UNOS policy change benefits high-priority patients without harming those at low priority. — Wolfson AM, DePasquale EC, Fong MW, Pandya K, Zhou L, Kawaguchi ES et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2022)
[8]
Trends and Outcomes of Cardiac Transplantation in the Lowest Urgency Candidates. — Fuery MA, Chouairi F, Natov P, Bhinder J, Rose Chiravuri M, Wilson L et al. Journal of the American Heart Association (2021)
[9]
De novo tacrolimus extended-release tablets (LCPT) versus twice-daily tacrolimus in adult heart transplantation: Results of a single-center non-inferiority matched control trial. — van Zyl JS, Sam T, Clark DM, Felius J, Doss AK, Kerlee KR et al. Clinical transplantation (2021)
[10]
Increasing the efficacy and safety of a human complement inhibitor for treating post-transplant cardiac ischemia reperfusion injury by targeting to a graft-specific neoepitope. — Zheng C, Sleiman MM, Yang X, He S, Atkinson C, Tomlinson S The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2021)
[11]
Sirolimus Adverse Event Profile in a Non-Clinical Trial Cohort of Heart Transplantation Patients. — Sallam K, Bhumireddy GP, Evuri VD, Abella JP, Haddad F, Valentine HA et al. Annals of transplantation (2021)
[12]
Blocking the IL-1 receptor reduces cardiac transplant ischemia and reperfusion injury and mitigates CMV-accelerated chronic rejection. — Jones IKA, Orloff S, Burg JM, Haese NN, Andoh TF, Chambers A et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2021)
[13]
Macrophage depletion of CMV latently infected donor hearts ameliorates recipient accelerated chronic rejection. — Haese NN, Burg JM, Andoh TF, Jones IKA, Kreklywich CN, Smith PP et al. Transplant infectious disease : an official journal of the Transplantation Society (2021)
[14]
Cardiac Magnetic Resonance Feature Tracking Global Longitudinal Strain and Prognosis After Heart Transplantation. — Shenoy C, Romano S, Hughes A, Okasha O, Nijjar PS, Velangi P et al. JACC. Cardiovascular imaging (2020)
[15]
Different Routes of Proton Pumps Inhibitors Co-Administration have Significant Impact on Mycophenolate Acid (MPA) Serum Levels in Heart Transplant Recipients. — Urbanowicz T, Straburzyńska-Migaj E, Casadei V, Bociański M, Jemielity M Annals of transplantation (2020)
[16]
Cell-free DNA donor fraction analysis in pediatric and adult heart transplant patients by multiplexed allele-specific quantitative PCR: Validation of a rapid and highly sensitive clinical test for stratification of rejection probability. — North PE, Ziegler E, Mahnke DK, Stamm KD, Thomm A, Daft P et al. PloS one (2020)
[17]
Discontinuing amiodarone treatment prior to heart transplantation lowers incidence of severe primary graft dysfunction. — Hoemann B, Takayama H, Jennings DL, Han J, Ando M, Restaino S et al. Clinical transplantation (2020)
[18]
Early outcomes for low-risk pediatric heart transplant recipients and steroid avoidance: A multicenter cohort study (Clinical Trials in Organ Transplantation in Children - CTOTC-04). — Lamour JM, Mason KL, Hsu DT, Feingold B, Blume ED, Canter CE et al. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2019)
[19]
Peritransplant VLA-4 blockade inhibits endogenous memory CD8 T cell infiltration into high-risk cardiac allografts and CTLA-4Ig resistant rejection. — Iida S, Miyairi S, Su CA, Abe T, Abe R, Tanabe K et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2019)
[20]
Influence of the Novel ATP-Competitive Dual mTORC1/2 Inhibitor AZD2014 on Immune Cell Populations and Heart Allograft Rejection. — Fantus D, Dai H, Ono Y, Watson A, Yokota S, Mohib K et al. Transplantation (2017)
[21]
Impact of Insurance Type on Initial Rejection Post Heart Transplant. — Breathett K, Willis S, Foraker RE, Smith S Heart, lung & circulation (2017)
[22]
Comparison of MMF with prednisone in terms of rejection and duration of activity of transplant in rabbits that underwent retroperitoneal heterotopic heart transplantation. — Aygün F, Efe D, Durgut K Cardiovascular journal of Africa (2015)
[23]
Design of the DRAGET Study: a multicentre controlled diagnostic study to assess the detection of acute rejection in patients with heart transplant by means of T2 quantification with MRI in comparison to myocardial biopsies. — Bonnemains L, Cherifi A, Girerd N, Odille F, Felblinger J BMJ open (2015)
[24]
Performance of gene-expression profiling test score variability to predict future clinical events in heart transplant recipients. — Crespo-Leiro MG, Stypmann J, Schulz U, Zuckermann A, Mohacsi P, Bara C et al. BMC cardiovascular disorders (2015)
[25]
Further evidence for sustained systemic inflammation in xenograft recipients (SIXR). — Iwase H, Ekser B, Zhou H, Liu H, Satyananda V, Humar R et al. Xenotransplantation (2015)
[26]
CD11c+ Dendritic Cells Accelerate the Rejection of Older Cardiac Transplants via Interleukin-17A. — Oberhuber R, Heinbokel T, Cetina Biefer HR, Boenisch O, Hock K, Bronson RT et al. Circulation (2015)
[27]
The International Heart Transplant Survival Algorithm (IHTSA): a new model to improve organ sharing and survival. — Nilsson J, Ohlsson M, Höglund P, Ekmehag B, Koul B, Andersson B PloS one (2015)
[28]
Transient blockade of delta-like Notch ligands prevents allograft rejection mediated by cellular and humoral mechanisms in a mouse model of heart transplantation. — Wood S, Feng J, Chung J, Radojcic V, Sandy-Sloat AR, Friedman A et al. Journal of immunology (Baltimore, Md. : 1950) (2015)
[29]
National decline in donor heart utilization with regional variability: 1995-2010. — Khush KK, Zaroff JG, Nguyen J, Menza R, Goldstein BA American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2015)
[30]
Comparison of listing strategies for allosensitized heart transplant candidates requiring transplant at high urgency: a decision model analysis. — Feingold B, Webber SA, Bryce CL, Park SY, Tomko HE, Comer DM et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2015)
[31]
Acute and chronic rejection: compartmentalization and kinetics of counterbalancing signals in cardiac transplants. — Kaul AM, Goparaju S, Dvorina N, Iida S, Keslar KS, de la Motte CA et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2015)
[32]
Ventricular assist devices and increased blood product utilization for cardiac transplantation. — Stone ML, LaPar DJ, Benrashid E, Scalzo DC, Ailawadi G, Kron IL et al. Journal of cardiac surgery (2015)
[33]
Early inflammatory markers are independent predictors of cardiac allograft vasculopathy in heart-transplant recipients. — Labarrere CA, Woods JR, Hardin JW, Jaeger BR, Zembala M, Deng MC et al. PloS one (2014)
[34]
Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation. — Doesch AO, Mueller S, Akyol C, Erbel C, Frankenstein L, Ruhparwar A et al. Drug design, development and therapy (2013)
[35]
Endogenous memory CD8 T cells are activated within cardiac allografts without mediating rejection. — Setoguchi K, Hattori Y, Iida S, Baldwin WM, Fairchild RL American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2013)
[36]
Low-dose rituximab therapy for antibody-mediated rejection in a highly sensitized heart-transplant recipient. — Aggarwal A, Pyle J, Hamilton J, Bhat G Texas Heart Institute journal (2012)
[37]
Intragraft CD11b(+) IDO(+) cells mediate cardiac allograft tolerance by ECDI-fixed donor splenocyte infusions. — Chen G, Kheradmand T, Bryant J, Wang S, Tasch J, Wang JJ et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2012)
[38]
Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. — Zhang T, Fresnay S, Welty E, Sangrampurkar N, Rybak E, Zhou H et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2011)
[39]
Alloantibodies prevent the induction of transplantation tolerance by enhancing alloreactive T cell priming. — Burns AM, Chong AS Journal of immunology (Baltimore, Md. : 1950) (2011)
[40]
Intermittent antibody-based combination therapy removes alloantibodies and achieves indefinite heart transplant survival in presensitized recipients. — Shariff H, Tanriver Y, Brown KL, Meader L, Greenlaw R, Mamode N et al. Transplantation (2010)
[41]
Raman spectroscopy detects cardiac allograft rejection with molecular specificity. — Chung YG, Tu Q, Cao D, Harada S, Eisen HJ, Chang C Clinical and translational science (2009)
[42]
Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action. — Hall BM, Pearce NW, Gurley KE, Dorsch SE The Journal of experimental medicine (1990)
[43]
Accelerated rejection of rat allografts after the rejection of rabbit skin grafts. — Brautbar C, Nelken D Clinical and experimental immunology (1967)
[44]
Heart Transplantation Utilizing Brain-Dead Donors Procured From Extended Distances Under the 2018 New Allocation Policy. — Kinjo R, Tavolacci SC, Khan S, Okumura K, Shimamura J, Spielvogel D et al. Clinical transplantation (2025)
[45]
Expression of c-jun/c-fos mRNA Indicates Persistent Myocardial Stretch During Asphyxia-Induced Cardiac Arrest. — Yokota Y, Kadowaki S, Yamazaki S, Nishida Y, Shishido T, Shimizu S et al. International heart journal (2024)
[46]
Electrostimulation suppresses allograft rejection via promoting lymphatic regulatory T cell migration mediated by lymphotoxin - lymphotoxin receptor β signaling. — Liu H, Dai H, Qiu F, Chen Y, Liang CL, Yang B et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2024)
[47]
Anticoagulation and Antiplatelet Regimen in Cardiac Transplant. Clinical Characteristics, Outcomes, and Blood Product Transfusion. — Groba Marco MDV, Saavedra Santana P, Gonzalez Del Castillo LM, Galvan Ruiz M, de Fernandez de Sanmamed M, Urso S et al. Clinical transplantation (2024)
[48]
Reactive Oxygen Species Responsive Multifunctional Fusion Extracellular Nanovesicles: Prospective Treatments for Acute Heart Transplant Rejection. — Lu X, Xu Z, Shu F, Wang Y, Han Y, Yang X et al. Advanced materials (Deerfield Beach, Fla.) (2024)
[49]
Impella 5.5 Bridge to Heart Transplant: An Institutional Series and a Closer Look at Device Removal Technique. — Clothier JS, Kobsa S, Praeger J, Bojko M, Dhillon A, Vaidya A et al. ASAIO journal (American Society for Artificial Internal Organs : 1992) (2024)
[50]
Heart Transplant Donor Selection Guidelines: Review and Recommendations. — Sathianathan S, Bhat G Current cardiology reports (2022)
[51]
A challenge to equity in transplantation: Increased center-level variation in short-term mechanical circulatory support use in the context of the updated U.S. heart transplant allocation policy. — Cascino TM, Stehlik J, Cherikh WS, Cheng Y, Watt TMF, Brescia AA et al. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2022)
[52]
Estimating filling pressures in paediatric heart transplant recipients using echocardiographic parameters and B-type natriuretic peptide. — Wisotzkey BL, Haileselassie B, Jorgensen N, Albers EL, Kemna MS, Soriano BD et al. Cardiology in the young (2022)
[53]
The effects of donor-specific antibody characteristics on cardiac allograft vasculopathy. — Wang M, Patel NJ, Zhang X, Kransdorf EP, Azarbal B, Kittleson MM et al. Clinical transplantation (2021)
[54]
Use of induction therapy in pediatric heart transplant recipients in Switzerland - Analysis of the Swiss national database. — Schweiger M, Erdil T, Di Bernardo S, Balmer C, Yildiz M, Kadner A Transplant immunology (2021)
[55]
Impact of risk-stratified mycophenolate dosing in heart transplantation. — Alam A, Van Zyl JS, Hall SA, Sam T Clinical transplantation (2021)
[56]
Switch from minimally invasive biventricular mechanical support to cardiopulmonary bypass during heart transplant. — Settepani F, Marianeschi SM, Costetti A, Russo CF European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2021)
[57]
Donor-specific antibodies in heart transplantation: can we afford the price or is it too steep to pay? — Nikolova AP, Kobashigawa JA Current opinion in organ transplantation (2020)
[58]
Cold-inducible RNA binding protein agonist enhances the cardioprotective effect of UW solution during extended heart preservation. — Pan HZ, Zhang LJ, Liu YW, Li YN, Su ZH, Meng J et al. Artificial organs (2020)
[59]
Quadritherapy vs standard tritherapy immunosuppressant regimen after heart transplantation: A propensity score-matched cohort analysis. — Nguyen LS, Suc G, Kheav VD, Coutance G, Carmagnat M, Rouvier P et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2020)
[60]
Outcomes of low-intensity biopsy surveillance for rejection in paediatric cardiac transplantation. — Evers PD, Jorgensen N, Hong B, Albers E, Kemna M, Friedland-Little J et al. Cardiology in the young (2019)
[61]
Crossing low-level donor-specific antibodies in heart transplantation. — Olymbios M, Kobashigawa JA Current opinion in organ transplantation (2019)
[62]
Cyclosporine A as a Cardioprotective Agent During Donor Heart Retrieval, Storage, or Transportation: Benefits and Limitations. — Gao L, Hicks M, Villanueva JE, Doyle A, Chew HC, Qui MR et al. Transplantation (2019)
[63]
Echocardiographic evaluation after pediatric heart transplant in Chile: initial application of a functional protocol with global longitudinal strain. — Trincado C, Molina V, Urcelay G, Dellepiane P Revista chilena de pediatria (2018)
[64]
Protective action of bone marrow mesenchymal stem cells in immune tolerance of allogeneic heart transplantation by regulating CD45RB — Hua F, Chen Y, Yang Z, Teng X, Huang H, Shen Z Clinical transplantation (2018)
[65]
Hearts transplanted after circulatory death in children: Analysis of the International Society for Heart and Lung Transplantation registry. — Kleinmahon JA, Patel SS, Auerbach SR, Rossano J, Everitt MD Pediatric transplantation (2017)
[66]
Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE). — Relbo Authen A, Grov I, Karason K, Gustafsson F, Eiskjaer H, Rådegran G et al. Clinical transplantation (2017)
[67]
Molecular Chimeric Recipient Precursor T Cells Promote Cardiac Allograft Survival in Mice. — Lu L, Zhang G, Li R, Zhao Z, Li W, Liu T et al. Transplantation proceedings (2015)
[68]
Conversion From Calcineurin Inhibitors to Mammalian Target-of-Rapamycin Inhibitors in Heart Transplant Recipients: A Meta-Analysis of Randomized Controlled Trials. — Qiu Y, Wang X, Fan J, Rao Z, Lu Y, Lin T Transplantation proceedings (2015)
[69]
Transplantation of the heart after circulatory death of the donor: time for a change in law? — Tibballs J, Bhatia N The Medical journal of Australia (2015)
[70]
Group visits in the pediatric heart transplant outpatient clinic. — Hollander SA, McDonald N, Lee D, May LJ, Doan LN, Kaufman BD et al. Pediatric transplantation (2015)
[71]
Extracorporeal Membrane Oxygenation as a Bridge to Pediatric Heart Transplantation: Effect on Post-Listing and Post-Transplantation Outcomes. — Dipchand AI, Mahle WT, Tresler M, Naftel DC, Almond C, Kirklin JK et al. Circulation. Heart failure (2015)
[72]
Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients. — Woillard JB, Saint-Marcoux F, Monchaud C, Youdarène R, Pouche L, Marquet P Pharmacological research (2015)
[73]
Bortezomib-containing regimen for primary treatment of early antibody-mediated cardiac allograft rejection: a case report. — Gazdic T, Svobodova E, Kubanek M, Kment M, Pagacova L, Viklicky O et al. Progress in transplantation (Aliso Viejo, Calif.) (2015)
[74]
Impact of Leukocyte Function-Associated Antigen-1 Blockade on Endogenous Allospecific T Cells to Multiple Minor Histocompatibility Antigen Mismatched Cardiac Allograft. — Kwun J, Farris AB, Song H, Mahle WT, Burlingham WJ, Knechtle SJ Transplantation (2015)
[75]
Reclassification of C4d-Positive Endomyocardial Biopsy (EMB) According to New International Society for Heart and Lung Transplantation (ISHLT) 2013 Categories for Reporting Pathologic Antibody-Mediated Rejection (pAMR): Preliminary Data from a Polish Single-Center Study. — Szymańska S, Grajkowska W, Sobieszczańska-Małek M, Zieliński T, Pronicki M Annals of transplantation (2015)
[76]
HGF Guides T Cells into the Heart. — Wolf D, Li J, Ley K Immunity (2015)
[77]
Low-dose 3-factor prothrombin complex concentrate for warfarin reversal prior to heart transplant. — Kantorovich A, Fink JM, Militello MA, Wanek MR, Smedira NG, Soltesz EG et al. The Annals of pharmacotherapy (2015)
[78]
Bloodless Orthotopic Heart Transplantation in a Jehovah's Witness. — Dallas T, Welsby I, Bottiger B, Milano C, Daneshmand M, Guinn N A & A case reports (2015)
[79]
Decrease in longitudinal strain in heart transplant recipients is associated with rejection. — Podrouzkova H, Bedanova H, Tretina M, Korinek J, Stepanova R, Hruskova J et al. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia (2015)
[80]
Adult heart transplantation with distant procurement and ex-vivo preservation of donor hearts after circulatory death: a case series. — Dhital KK, Iyer A, Connellan M, Chew HC, Gao L, Doyle A et al. Lancet (London, England) (2015)
[81]
The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial. — Arora S, Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Bøtker HE et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2015)
[82]
C4d immunostaining is an independent predictor of cardiac allograft vasculopathy and death in heart transplant recipients. — Luk A, Alba AC, Butany J, Tinckam K, Delgado D, Ross HJ Transplant international : official journal of the European Society for Organ Transplantation (2015)
[83]
Myocardial strain and strain rate from speckle-tracking echocardiography are unable to differentiate asymptomatic biopsy-proven cellular rejection in the first year after cardiac transplantation. — Ambardekar AV, Alluri N, Patel AC, Lindenfeld J, Dorosz JL Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography (2015)
[84]
Anti-OX40L monoclonal antibody prolongs secondary heart allograft survival based on CD40/CD40L and LFA-1/ICAM-1 blockade. — Dai H, Peng F, Lin M, Xia J, Yu S, Lan G et al. Transplant immunology (2015)
[85]
Twelve-hour reanimation of a human heart following donation after circulatory death. — Rosenfeldt F, Ou R, Woodard J, Esmore D, Marasco S Heart, lung & circulation (2014)
[86]
Kinetics of functionally distinct T-lymphocyte subsets in heart transplant recipients after induction therapy with anti-CD25 monoclonal antibodies. — Lanio N, Sarmiento E, Gallego A, Navarro J, Palomo J, Fernandez-Yañez J et al. Transplant immunology (2013)
[87]
Cyclosporine immunosuppression does not prevent the production of donor-specific antibody capable of mediating allograft vasculopathy. — Gareau AJ, Nashan B, Hirsch GM, Lee TD The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2012)
[88]
Modified CD4(+) T-cell response in recipients of old cardiac allografts. — Denecke C, Ge X, Jurisch A, Kleffel S, Kim IK, Padera RF et al. Transplant international : official journal of the European Society for Organ Transplantation (2012)
[89]
Successful use of the TandemHeart percutaneous ventricular assist device as a bridge to recovery for acute cellular rejection in a cardiac transplant patient. — Velez-Martinez M, Rao K, Warner J, Dimaio J, Ewing G, Mishkin JD et al. Transplantation proceedings (2011)
[90]
Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. — Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2011)
[91]
Favorable short-term outcome of transplanted hearts selected from marginal donors by pharmacological stress echocardiography. — Bombardini T, Gherardi S, Arpesella G, Maccherini M, Serra W, Magnani G et al. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography (2011)
[92]
The fibrin-derived peptide Bbeta(15-42) significantly attenuates ischemia-reperfusion injury in a cardiac transplant model. — Wiedemann D, Schneeberger S, Friedl P, Zacharowski K, Wick N, Boesch F et al. Transplantation (2010)
[93]
Indications, tolerance and complications of a sirolimus and calcineurin inhibitor immunosuppression regimen: intermediate experience in pediatric heart transplantation recipients. — Matthews K, Gossett J, Kappelle PV, Jellen G, Pahl E Pediatric transplantation (2010)
[94]
Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients. — Sheshgiri R, Gustafsson F, Sheedy J, Rao V, Ross HJ, Delgado DH The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2009)
[95]
Utility of virtual crossmatch in sensitized patients awaiting heart transplantation. — Stehlik J, Islam N, Hurst D, Kfoury AG, Movsesian MA, Fuller A et al. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2009)
[96]
Incidence, predictors, and outcomes of cardiac pacing after cardiac transplantation: an 11-year retrospective analysis. — Woo GW, Schofield RS, Pauly DF, Hill JA, Conti JB, Kron J et al. Transplantation (2008)
[97]
Decay-accelerating factor expression may provide immunoprotection against antibody-mediated cardiac allograft rejection. — González-Stawinski GV, Tan CD, Smedira NG, Starling RC, Rodríguez ER The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2008)
[98]
Enhanced allograft survival and modulation of T-cell alloreactivity induced by inhibition of MMP/ADAM enzymatic activity. — Eaton VL, Lerret NM, Velásquez-Lopera MM, John R, Caicedo M, DeCresce RP et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2008)
[99]
Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients. — Kijpittayarit-Arthurs S, Eid AJ, Kremers WK, Pedersen RA, Dierkhising RA, Patel R et al. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2007)
[100]
Attrition from heart transplant waiting list for patients on ventricular assist devices is not affected by desensitization strategies. — Gonzalez-Stawinski GV, Cook DJ, Smedira NG, Navia JL, Taylor DO, Yamani MH et al. Transplantation proceedings (2007)